Left ventricular thrombus after myocardial infarction

Article written and reviewed by Dr Luca Moretti

Left ventricular thrombus after myocardial infarction is an intracavitary thrombotic mass that adheres to the endocardium of an injured region, almost always near severely hypokinetic, akinetic, or dyskinetic segments. The classic phenotype is an apical thrombus after a large anterior STEMI; intracavitary thrombosis is not a remnant of the coronary thrombus. It originates in the ventricle after necrosis and may embolize throughout the arterial circulation.
Its frequency has declined with early reperfusion, antithrombotic therapy, and limitation of infarct size, but it depends strongly on the imaging technique and timing. Standard echocardiography misses small or laminated thrombi, whereas contrast-enhanced MRI detects a greater proportion; residual risk remains relevant in large anteroapical infarctions. A negative very early examination does not exclude subsequent formation.

The thrombus is often asymptomatic and is discovered during imaging of ventricular function. The first manifestation may be a stroke or peripheral embolism, so identifying high-risk patients and selecting the appropriate method have immediate therapeutic consequences; embolic prevention, however, requires anticoagulation, which is added to the antiplatelet agents used after a coronary syndrome. Benefit and bleeding must be balanced individually.
Contemporary recommendations are derived from guidelines, scientific statements, and relatively small studies. A vitamin K antagonist remains the historical reference, whereas DOACs are reasonable alternatives in selected patients, without proof of superiority and with limited data on major clinical events; the indicative duration is approximately three months for documented post-infarction thrombus. Follow-up imaging, not the calendar alone, determines whether to stop, extend, or modify treatment.

The clinical problem does not end with recognition of the mass. It is necessary to determine when it formed, how likely it is to embolize, how reliable the image is, which antiplatelet agents are still required, and whether the apical substrate may recover; an integrated assessment avoids two opposing errors: undertreating a mobile thrombus or prolonging high-risk anticoagulation for a questionable fibrotic remnant; these decisions require serial documentation and shared decision-making with the patient.
Published percentages are not directly comparable: echocardiographic cohorts often include early, noncontrast examinations, whereas MRI studies select stable patients and visualize smaller laminated thrombi. Estimates increase from all infarctions to anterior STEMI and increase further when apical dysfunction and reduced ejection fraction coexist. The imaging-dependent incidence must be reported together with the method. An isolated number does not describe an individual patient's risk.

Etiology, risk factors, pathogenesis, and pathophysiology

The pathogenesis reproduces Virchow's triad: blood stasis, injury to the endocardial surface, and a prothrombotic state. An extensive anterior infarction disrupts the physiological vortex and creates an apical region in which blood remains, while necrosis and tissue exposure activate platelets and coagulation; the thrombogenic triad acts simultaneously. The relative contribution of the three components varies among patients and during the different phases after infarction.
Akinesia reduces blood renewal near the wall, whereas dyskinesia and aneurysm create a recessed cavity with slow, recirculating flow. Stasis increases when the ejection fraction is low and the apex does not empty during systole; apical dysfunction predicts risk better than global ejection fraction alone. Moderately reduced overall function may conceal a completely immobile apex.

Endocardial injury results from transmural or extensive subendocardial necrosis, inflammation, and denudation of the surface. Infarcted tissue exposes procoagulant factors and loses antithrombotic properties, allowing the initial adhesion of fibrin and cells; the endocardial substrate anchors the thrombus to the scar. Early reperfusion limits this process by reducing infarct size and transmurality.
Infarction induces systemic activation of coagulation, platelets, and inflammation, with a transient increase in thrombogenicity. Diabetes, cancer, antiphospholipid syndrome, or other prothrombotic conditions may amplify risk but should not be investigated indiscriminately if the post-infarction context is sufficient. The hypercoagulable state completes the local mechanism. A history of unusual thromboses may justify a targeted evaluation.

Risk is greatest after an anterior infarction involving the left anterior descending artery, especially with delayed reperfusion, a high biomarker peak, aneurysm, and an ejection fraction below 30 percent. Isolated inferior infarctions produce thrombus much less frequently; anatomical predictors guide surveillance. They do not, however, justify diagnosing a thrombus without visualizing it.
An initial thrombus may be soft, protruding, and mobile, exposed to flow forces; over time it may flatten, organize, become fibrotic, and adhere firmly. Mobility and protrusion are associated with greater concern for embolism, but a laminated thrombus may also embolize; thrombus morphology modifies risk estimation. No echocardiographic form automatically makes initial anticoagulation unnecessary.

Recovery of contractility reduces stasis and promotes resolution, whereas aneurysm and scar maintain the substrate even after the mass disappears; this explains recurrence after discontinuation and the need to distinguish anatomical resolution from correction of risk; a persistent substrate may justify prolonged follow-up. Indefinite anticoagulation, however, is not supported by universal evidence.
Flow, pressure, and contraction interact with the thrombus surface. A protruding mass experiences greater stress, whereas organization creates connections with the endocardium; the anticoagulant prevents further propagation, but removal depends on fibrinolytic systems and hemodynamic recovery; biological resolution is not immediate dissolution caused by the drug; this distinction explains why images change over weeks and why follow-up after only a few days may be premature.

Pathological anatomy, classification, and evolution

The thrombus is located predominantly at the apex, adhering to the infarcted anterior, septal, or inferior segment. It may occupy a small endocardial depression, line a scar, or protrude into the cavity with a recognizable stalk; the apical location reflects the territory and stasis. Basal or multiple thrombi require a more careful search for alternative diagnoses and systemic conditions.
The most useful classification distinguishes a mural or laminated thrombus, which is flat and adherent, from a protruding thrombus, which projects into the lumen, and a mobile thrombus, which moves independently of the wall. Size, contours, echogenicity, and relationship with the endocardium complete the description; a protruding shape indicates more recent or less organized tissue. Terminology must remain consistent in serial assessments.

On gross examination, a recent thrombus contains fibrin, platelets, and erythrocytes; it is subsequently infiltrated by cells, capillaries, and collagen. Organization may make its echogenicity similar to the wall and make it difficult to distinguish from trabeculae or scar; an organized thrombus may persist despite adequate anticoagulation. Failure to disappear does not automatically demonstrate pharmacological failure or a need for thrombolysis.
Most form within the first two weeks, but the exact timing varies with imaging and recovery. An echocardiogram in the first 24–48 hours may precede formation, whereas early discharge reduces the opportunity to identify it later; the diagnostic window requires a risk-based strategy. In high-risk anteroapical phenotypes, repeat imaging may be appropriate.

During anticoagulation, the mass may shrink, flatten, or disappear. Echocardiographic resolution does not always equal resolution detected by MRI because small avascular remnants may be missed by standard echocardiography; apparent resolution depends on the method used. Follow-up should use a sufficiently sensitive technique that is preferably comparable to the diagnostic technique.
A persistent laminated, calcified, and immobile thrombus may represent organized material with lower embolic risk, whereas persistent protrusion or mobility maintains greater concern. Switching anticoagulants or extending treatment is a consensus-based decision not supported by large studies; morphological persistence must be reassessed with accurate imaging. Adherence and dose should be verified before declaring resistance.

Recurrence after documented resolution is more likely with an apical aneurysm, previous stroke, and persistent dysfunction. A contemporary observational study reports nonnegligible recurrence, but does not define a universally valid threshold for indefinite treatment; the risk of recurrence survives the first resolution. Imaging and future decisions must be tailored to the ventricular substrate.
Calcification of a chronic thrombus may appear on CT and suggests prolonged organization, while signal heterogeneity on MRI changes with hemoglobin, fibrin, and fibrosis; these features help date the mass approximately but do not provide a precise clock; thrombus dating remains probabilistic. The history of previous examinations and the timeline of the infarction are essential for interpreting the finding.

Size and mobility may change even without complete resolution. A reduction in area accompanied by loss of protrusion is biologically favorable, but it is not a validated outcome that always permits treatment to be shortened; conversely, growth during treatment requires immediate investigation; the morphological trajectory adds information to the binary presence or absence. Reliable comparisons require similar views, scale, and technique, preferably with storage of the original images.

Signs and symptoms

The thrombus itself generally does not produce pain, a murmur, or specific cardiac symptoms. Dyspnea and reduced exercise tolerance more often result from the infarction, ventricular dysfunction, or aneurysm that constitute the substrate; the silent presentation makes targeted screening central. A normal physical examination does not reduce risk when imaging shows extensive apical akinesia.
Ischemic stroke may present with unilateral weakness or loss of sensation, speech disturbance, gaze deviation, visual deficit, or a sudden disturbance of balance; these symptoms require immediate activation of the neurological pathway, without waiting for a deferred cardiological assessment; an acute neurological deficit may be the first evidence of the thrombus. The therapeutic window for stroke remains the priority.

Limb embolism causes sudden pain, pallor, coldness, absent pulses, paresthesias, or weakness. Early recognition permits limb revascularization while the cardiac source is investigated in parallel. Peripheral ischemia is a vascular emergency. Anticoagulation does not exclude embolism if the dose, adherence, or time in the therapeutic range is insufficient.
Renal or splenic emboli may produce flank or upper-quadrant pain, hematuria, fever, and elevated enzymes, whereas mesenteric infarction causes abdominal pain that is often disproportionate to the initial findings; these presentations are less common but potentially serious; the systemic distribution reflects the arterial circulation. Lesions in multiple territories strengthen the embolic hypothesis.

The cardiovascular examination documents signs of heart failure, pressure, rhythm, and complications of infarction. Atrial fibrillation constitutes an alternative embolic source and independently affects the indication for anticoagulation, but does not exclude the simultaneous presence of ventricular thrombus; multiple embolic sources must be considered. Etiological diagnosis is especially important if the event occurs during treatment.
An early embolic event may originate from a thrombus that is still mobile, whereas a late stroke requires reassessment of the ventricle and other causes such as atrial fibrillation, aortic plaque, or carotid disease. Timing guides but does not determine the source; the temporal relationship must be supported by imaging. Automatically attributing every stroke to the previous infarction may conceal a treatable cause.

Signs of bleeding during anticoagulation include melena, hematemesis, hematuria, extensive bruising, sudden headache, or a fall in hemoglobin. Combined treatment with antiplatelet agents increases risk and requires patient education and monitoring; bleeding warning signs must be evaluated urgently. Self-discontinuation, however, exposes the patient to embolism and should be prevented through clear instructions.
The absence of embolic symptoms does not demonstrate that the thrombus is harmless, while transient symptoms may be mistaken for hypotension, neuropathy, or post-infarction recovery. Brief focal episodes, sudden limb pain, or visual changes warrant evaluation even if they resolve; transient events may represent emboli or ischemic attacks. A precise history changes the urgency of imaging and the antithrombotic strategy.

Investigations and diagnosis

Transthoracic echocardiography is the first-line examination after infarction because it is available and repeatable and simultaneously assesses function, wall motion, aneurysm, and mechanical complications. The thrombus appears as a mass distinct from the endocardium, present in multiple views and adjacent to an abnormal region; visualization of the apex must be complete and without apical foreshortening. Artifacts and trabeculae must not be diagnosed from a single image.
Apical four-, two-, and three-chamber views are optimized by moving the transducer to include the true apex. The thrombus may be echodense or isoechoic to myocardium, laminated or mobile, and should be measured in orthogonal dimensions; serial documentation includes location, area, protrusion, and mobility. A vague description prevents assessment of response.

Echocardiographic contrast opacifies the cavity and improves endocardial border definition, increasing sensitivity when the apex is poorly visualized or suspicion remains high. A wall-adherent filling defect supports thrombus; intracavitary contrast is not necessary in every echocardiogram. It becomes important when the result changes anticoagulation.
Cardiac magnetic resonance imaging with late gadolinium enhancement has greater sensitivity and very high specificity. Avascular thrombus does not accumulate gadolinium and may be distinguished from myocardium, tumor, and blood by dedicated long-inversion-time sequences; contrast-enhanced MRI is preferred when echocardiography is equivocal or discordant. It may also quantify scar, aneurysm, and the substrate for stasis.

Cardiac CT may identify a filling defect, especially with delayed acquisitions, and is an alternative when MRI is unavailable or contraindicated. Radiation, iodine, and the possibility of slow flow mimicking thrombus limit indiscriminate use; delayed-phase CT requires appropriate protocols. Transesophageal echocardiography adds little for the apex and is not the method of choice.

Practical criteria for confirming and characterizing a left ventricular thrombus

• Intracavitary mass: structure distinct from the endocardial border and visible in multiple planes.
• Compatible substrate: akinesia, dyskinesia, aneurysm, or a large scar in the adjacent segment.
• Described morphology: dimensions, laminated or protruding shape, mobility, and attachment to the wall.
• Artifacts excluded: trabeculae, papillary muscles, apical foreshortening, and reverberations recognized.
• Advanced imaging: echocardiographic contrast or MRI used when the result remains uncertain.

The differential diagnosis includes apical trabeculation, a false tendon, papillary muscle, noncompaction, tumor, rare vegetation, and artifact. An aneurysm may contain slow flow that appears as spontaneous echo contrast without a defined mass; spontaneous contrast indicates stasis but is not equivalent to thrombus. An uncertain diagnosis should be resolved before exposing the patient to triple therapy.
In high-risk patients with a negative initial examination, repetition during hospitalization or within the first two weeks may detect late formation. There is no universal schedule for all infarctions, and indiscriminate surveillance has a low yield; selective surveillance focuses on anterior STEMI, an akinetic apex, and a low ejection fraction. An embolic event is always a new indication for more sensitive imaging.

The report should explicitly state whether the apex was visualized with diagnostic quality. Phrases such as “no thrombus” are too categorical when the window is incomplete; in such cases, the clinician should select contrast or MRI according to pretest probability and the therapeutic consequences; diagnostic quality is part of the result. A false negative may delay anticoagulation, whereas a false positive adds bleeding risk without benefit.

Treatment and prognosis

A documented post-infarction ventricular thrombus generally requires oral anticoagulation to reduce embolism and promote resolution. The 2025 ACS guideline indicates approximately three months for most patients, followed by imaging to determine whether the thrombus persists; anticoagulant therapy should begin after bleeding assessment. Active bleeding or hemorrhagic transformation of a stroke requires multidisciplinary decisions.
Warfarin is the treatment with the longest tradition and is generally titrated to an INR of 2.0–3.0, with frequent monitoring and attention to diet and interactions. In the initial phases, parenteral anticoagulation may be used until the effect is therapeutic, according to the clinical scenario; time in the therapeutic range determines efficacy and safety. Repeatedly subtherapeutic values leave the patient exposed to embolism.

DOACs, especially apixaban and rivaroxaban, are used off-label in many systems and considered a reasonable alternative by the AHA scientific statement. Meta-analyses of small randomized trials published in 2025 show resolution similar to VKAs, without demonstrated differences in stroke, mortality, or bleeding. The randomized evidence remains underpowered for rare events. It is not scientifically correct to claim superiority of DOACs.
The choice considers renal and hepatic function, mechanical valves, antiphospholipid syndrome, adherence, interactions, access to monitoring, and informed preference. DOACs are not appropriate for mechanical prosthetic valves, and some conditions require a VKA; an individualized choice matters more than convenience alone. Unvalidated reduced doses must not be used solely because of concern about bleeding.

After PCI, the patient often takes aspirin and a P2Y12 inhibitor; adding anticoagulation creates triple therapy and increases bleeding. Triple exposure is generally limited and an anticoagulant plus a single antiplatelet agent is preferred when possible, adjusted to stent thrombosis and bleeding risk; antithrombotic simplification requires a cardiological decision; this regimen is derived mainly from studies of atrial fibrillation after PCI and is applied to ventricular thrombus by extrapolation, not on the basis of specific randomized comparisons.
Prophylactic anticoagulation in the absence of thrombus is not routine, even after anterior infarction, because modern evidence is limited and the potential benefit competes with bleeding from combination therapy. In an anteroapical STEMI with akinesia, it may be discussed for one to three months after individual assessment; selective prophylaxis derives from weak evidence and consensus. Repeat imaging may avoid treating many patients who will not form a thrombus.

Follow-up at approximately three months verifies resolution and recovery of wall motion. If the mass persists, especially if protruding or mobile, adherence and intensity are checked, a more sensitive technique is considered, and treatment is extended or changed on an individualized basis; the decision to discontinue requires reliable images. Aneurysm, previous embolism, and persistent dysfunction may favor surveillance or longer treatment.
Heart failure therapy, revascularization, and secondary prevention reduce remodeling and new events but do not replace anticoagulation for an existing thrombus. Surgical thrombectomy is exceptional and reserved for selected cases or cardiac surgery that is already necessary; treatment of the substrate improves overall prognosis. Systemic thrombolysis of ventricular thrombus is not a routine strategy because of bleeding and embolic risk.

Before discharge, the medication, dose, provisional duration, associated antiplatelet agent, laboratory monitoring, warning signs, and imaging appointment must be defined. Warfarin requires a network that ensures timely INR testing; DOACs require renal function and interactions to be checked at every clinical change; the continuity plan is part of treatment. A prescription without follow-up simultaneously exposes the patient to underdosing, overdosing, and inappropriate discontinuation.
Invasive procedures, noncardiac surgery, and bleeding require temporary management that takes recent PCI and thrombus morphology into account. Interruption and resumption do not follow a single regimen: urgency, renal function, hemostasis, anticoagulant type, and stent risk change the balance; periprocedural management must be planned by the treating clinicians. Heparin bridging is not automatically necessary for every brief interruption and is not harmless.

Complications

Systemic embolism is the most feared specific complication. Fragments may reach the brain, limbs, kidneys, spleen, or mesentery, causing permanent disability, loss of an organ, or death; embolic risk is greatest during the first months and with mobile or protruding thrombi. It does not become zero merely because the mass is laminated or the patient is asymptomatic.
Stroke requires coordination between neurology and cardiology because thrombolysis or thrombectomy depends on timing, imaging, and anatomy, while initiation of anticoagulation after the event must balance recurrence and hemorrhagic transformation; post-stroke timing is not uniform. Cerebral infarct size, hemorrhage, and cardiac stability guide the timing.

Peripheral emboli may require embolectomy, thrombectomy, or endovascular treatment in addition to anticoagulation. An event during treatment requires verification of adherence, INR, dose, interactions, and new morphology, without automatically concluding that the drug class is ineffective. Embolism during treatment requires complete reassessment. A concomitant aortic or atrial source must be excluded.
Major bleeding may be gastrointestinal, intracranial, urinary, or at the PCI access site. Age, renal failure, anemia, previous bleeding, and the antithrombotic combination increase risk; a bleeding complication may nullify the preventive benefit. The number and duration of antithrombotic agents must be reduced to the minimum effective regimen.

Thrombus persistence creates therapeutic uncertainty. An organized, calcified mass may fail to resolve despite having lost much of its thrombogenicity, whereas a still-mobile mass suggests active risk; large studies do not define the optimal choice; a persistent thrombus requires characterization, not merely measurement. Extending treatment indefinitely creates cumulative bleeding risk.
Recurrence after discontinuation may occur if aneurysm, akinesia, and scar remain. New observational studies associate recurrence with apical aneurysm and previous stroke but do not provide a rule valid for every patient; late recurrence justifies education about embolic symptoms. A new event or ventricular deterioration requires repeat imaging.

Finally, the thrombus often identifies a large infarction and a prognosis also determined by heart failure, arrhythmias, and sudden death. Focusing solely on disappearance of the mass may neglect ventricular function, defibrillator assessment, rehabilitation, and secondary prevention; overall prognosis derives mainly from the myocardial substrate. Complete care integrates embolic prevention and permanent treatment of ischemic heart disease.
The psychological consequences are not negligible: fear of stroke or bleeding may promote hypervigilance, reduce activity, and impair adherence. Balanced information should explain that risk is reduced, not eliminated, and that activities, travel, or procedures require individual guidance rather than blanket prohibitions. Risk communication supports safe decisions. Cardiac rehabilitation and the primary care physician help coordinate treatment, monitoring, and return to daily life.

A false-positive diagnosis is itself a complication because it exposes the patient to months of anticoagulation and modifies antiplatelet therapy; a false negative instead leaves an embolic patient unprotected. The cost of error is high in both directions; diagnostic certainty must be proportionate to treatment risk. When images and the clinical presentation are discordant, a more sensitive method is preferable to a decision based on impression alone.
Coordination becomes even more delicate when atrial fibrillation, a prosthetic valve, venous thrombosis, or cancer coexists, because the indication and duration of anticoagulation no longer depend on the ventricular thrombus alone. Resolution of the mass may not permit discontinuation if another indication remains, whereas bleeding requires priorities to be ordered. Concomitant indications must be recorded separately; in this way, every future modification retains a verifiable rationale and does not derive from therapeutic inertia.